Potent SARS-CoV2-specific T-cell Response in Asymptomatic Hemodialysis Patients with Hidden COVID-19 Infection History

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2023 Mar 21

PMID 36941528

Authors

Jalal Etemadi

Roza Motavalli

Seyed Alireza Mirghaffari

Mohammad Sadegh Soltani-Zangbar

Mahsa Hajivalili

Javad Ahmadian Heris

Bahram Niknafs

Sepideh Zununi

Mohammadreza Sadeghi

Sadraddin Rasi Hashemi

Hamid Tayebi Khosroshahi

Mehdi Yousefi

Affiliations

Soon will be listed here.

Abstract

Background: COVID-19-related immune responses in patients with end-stage renal disease (ESRD) are characterized in detail by the humoral response, but their cellular immunity has not been clarified. Here, we evaluated virus-specific T cells in parallel with serology-related tests.

Methods: In this study, 104 ESRD patients at the hemodialysis ward of Imam Reza hospital at Tabriz (Iran) were enrolled. After blood sampling, SARS-CoV2-specific humoral and cellular immune responses were evaluated by SARS-CoV2-specific IgM/IgG ELISA and peptide/MHCI-Tetramers flow cytometry, respectively.

Results: Our results showed that 14 (13.5%) and 45 (43.3%) patients had specific SARS-CoV2 IgM and IgG in their sera, respectively. Immunophenotyping for SARS-CoV2-specific CD8 T lymphocytes revealed that 68 (65.4%) patients had these types of cells. Among SARS-CoV2-specific CD8 T lymphocytes positive subjects, 13 and 43 individuals had positive results for specific SARS-CoV2 IgM and IgG existence, respectively. Also, there was a relationship between specific SARS-CoV2 IgM (p = 0.031) and IgG (p < 0.0001) existence and having SARS-CoV2-specific TCD8 lymphocytes in the studied population.

Conclusion: Despite not having clinical symptoms, a high rate of SARS-CoV2-specific T-cell response in asymptomatic ESRD patients may reveal a high burden of asymptomatic COVID-19 infection in these patients.

Citing Articles

Potent SARS-CoV2-specific T-cell response in asymptomatic hemodialysis patients with hidden COVID-19 infection history.

Etemadi J, Motavalli R, Mirghaffari S, Soltani-Zangbar M, Hajivalili M, Heris J J Clin Lab Anal. 2023; 37(5):e24863.

PMID: 36941528 PMC: 10098065. DOI: 10.1002/jcla.24863.

References

Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F . Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology. 2020; 9(5):e01136. PMC: 7202656. DOI: 10.1002/cti2.1136. View

Soltani-Zangbar M, Aghebati-Maleki L, Hajivalili M, Haji-Fatahaliha M, Motavalli R, Mahmoodpoor A . Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation. Gene Rep. 2021; 23:101140. PMC: 8041740. DOI: 10.1016/j.genrep.2021.101140. View

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

Schultze J, Aschenbrenner A . COVID-19 and the human innate immune system. Cell. 2021; 184(7):1671-1692. PMC: 7885626. DOI: 10.1016/j.cell.2021.02.029. View

Amor S, Fernandez Blanco L, Baker D . Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. Clin Exp Immunol. 2020; 202(2):193-209. PMC: 7537271. DOI: 10.1111/cei.13523. View

Schulien I, Kemming J, Oberhardt V, Wild K, Seidel L, Killmer S . Characterization of pre-existing and induced SARS-CoV-2-specific CD8 T cells. Nat Med. 2020; 27(1):78-85. DOI: 10.1038/s41591-020-01143-2. View

Etemadi J, Motavalli R, Mirghaffari S, Soltani-Zangbar M, Hajivalili M, Heris J . Potent SARS-CoV2-specific T-cell response in asymptomatic hemodialysis patients with hidden COVID-19 infection history. J Clin Lab Anal. 2023; 37(5):e24863. PMC: 10098065. DOI: 10.1002/jcla.24863. View

Madariaga M, Guthmiller J, Schrantz S, Jansen M, Christensen C, Kumar M . Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med. 2020; 289(4):559-573. PMC: 7675325. DOI: 10.1111/joim.13185. View

Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S . Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant. 2021; 36(9):1709-1716. PMC: 8194560. DOI: 10.1093/ndt/gfab179. View

10.

Clarke C, Prendecki M, Dhutia A, Gan J, Edwards C, Prout V . Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int. 2021; 99(6):1470-1477. PMC: 7992297. DOI: 10.1016/j.kint.2021.03.009. View

11.

Soltani-Zangbar M, Parhizkar F, Abdollahi M, Shomali N, Aghebati-Maleki L, Farid S . Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives. Cell Commun Signal. 2022; 20(1):131. PMC: 9421625. DOI: 10.1186/s12964-022-00948-7. View

12.

Sattler A, Angermair S, Stockmann H, Heim K, Khadzhynov D, Treskatsch S . SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. J Clin Invest. 2020; 130(12):6477-6489. PMC: 7685725. DOI: 10.1172/JCI140965. View

13.

Soltani-Zangbar M, Mahmoodpoor A, Dolati S, Shamekh A, Valizadeh S, Yousefi M . Serum levels of vitamin D and immune system function in patients with COVID-19 admitted to intensive care unit. Gene Rep. 2022; 26:101509. PMC: 8761022. DOI: 10.1016/j.genrep.2022.101509. View

14.

Etemadi J, Bordbar S, Soltani-Zangbar M, Hajivalili M, Aghebati-Maleki L, Motavalli R . Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients. Immunol Invest. 2021; 51(4):993-1004. DOI: 10.1080/08820139.2021.1899202. View

15.

Soltani-Zangbar M, Parhizkar F, Ghaedi E, Tarbiat A, Motavalli R, Alizadegan A . A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients. Cell Commun Signal. 2022; 20(1):106. PMC: 9287826. DOI: 10.1186/s12964-022-00903-6. View

16.

Motavalli R, Abdelbasset W, Rahman H, Achmad M, Sergeevna N, Zekiy A . The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses. IUBMB Life. 2021; 73(8):1005-1015. PMC: 8426673. DOI: 10.1002/iub.2516. View

17.

Montenegro P, Brotons C, Serrano J, Fernandez D, Garcia-Ramos C, Ichazo B . Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain. Fam Pract. 2020; 38(2):154-159. PMC: 7797756. DOI: 10.1093/fampra/cmaa096. View

18.

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X . COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27(5):1451-1454. PMC: 7091918. DOI: 10.1038/s41418-020-0530-3. View

19.

Candon S, Guerrot D, Drouot L, Lemoine M, Lebourg L, Hanoy M . T cell and antibody responses to SARS-CoV-2: Experience from a French transplantation and hemodialysis center during the COVID-19 pandemic. Am J Transplant. 2020; 21(2):854-863. PMC: 7675512. DOI: 10.1111/ajt.16348. View

20.

Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L . IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2020; 13(577). PMC: 7857408. DOI: 10.1126/scitranslmed.abd2223. View